Those statements in the following discussion that are not historical in nature should be considered forward-looking statements that are inherently uncertain. Actual results and the timing of the events may differ materially from those contained in these forward-looking statements due to a number of factors, including those discussed in the Cautionary Statement Regarding Forward-Looking Statements and Risk Factors set forth elsewhere in this Annual Report. Overview We are a biopharmaceutical comp...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-19 | 2025-12-31 | 0001438533-26-000014 | EDGAR | 103K words |
| 2025-02-21 | 2024-12-31 | 0001438533-25-000010 | EDGAR | — |
| 2024-02-20 | 2023-12-31 | 0001438533-24-000005 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001438533-23-000008 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001438533-22-000008 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001438533-21-000008 | EDGAR | — |
| 2020-02-24 | 2019-12-31 | 0001438533-20-000004 | EDGAR | — |
| 2019-02-26 | 2018-12-31 | 0001438533-19-000003 | EDGAR | — |
| 2018-02-27 | 2017-12-31 | 0001438533-18-000006 | EDGAR | — |
| 2017-03-01 | 2016-12-31 | 0001438533-17-000005 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0001438533-25-000056 | EDGAR | 63K words |
| 2025-08-06 | 2025-06-30 | 0001438533-25-000046 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001438533-25-000026 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0001438533-24-000048 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001438533-24-000031 | EDGAR | — |
| 2024-05-06 | 2024-03-31 | 0001438533-24-000020 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001438533-23-000048 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001438533-23-000039 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001438533-23-000024 | EDGAR | — |
| 2022-10-27 | 2022-09-30 | 0001438533-22-000051 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001438533-22-000032 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001438533-22-000025 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-19 | 0001438533-26-000013 | EDGAR | 6K words |
| 2026-01-13 | 0001438533-26-000005 | EDGAR | — |
| 2026-01-12 | 0001438533-26-000003 | EDGAR | — |
| 2025-10-30 | 0001438533-25-000055 | EDGAR | — |
| 2025-09-10 | 0001438533-25-000049 | EDGAR | — |
| 2025-08-06 | 0001438533-25-000045 | EDGAR | — |
| 2025-05-16 | 0001438533-25-000034 | EDGAR | — |
| 2025-05-15 | 0001438533-25-000032 | EDGAR | — |
| 2025-05-01 | 0001438533-25-000025 | EDGAR | — |
| 2025-04-30 | 0001438533-25-000020 | EDGAR | — |
269 total filings indexed. 237 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001438533 |
| Ticker | TVTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | CA |
| Website | https://www.travere.com |
| Listed | 2003-07-23 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report